UCB has announced that it will be amending the scope of its collaborative partnership with Otsuka Pharmaceutical, in order to focus solely on central nervous system (CNS) disorders. Under the terms of the reorganised alliance, the companies will be discontinuing their joint work in the field of immunology, which links in with Otsuka’s decision to focus its future operations on CNS disorders and oncology. As a result of this, UCB will be continuing with the further development of its immunology pipeline in Japan independently, commencing with plans to launch its drug Cimzia in the Asian nation.
